From: Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients
Unadjusted (β, P) (r2 = 0.23) | Model 1 (β, P) (r2 = 0.27) | Model 2 (β, P) (r2 = 0.27) | Model 3 (β, P) (r2 = 0.21) | |
---|---|---|---|---|
hsCRP (mg/L) | 0.49 (0.001) | 0.52 (0.001) | 0.54 (0.001) | 0.44 (0.05) |
Age (years) | 0.02 (0.90) | −0.002 (0.98) | − 0.03 (0.85) | |
Gender (female) | 0.28 (0.04) | 0.27 (0.07) | 0.30 (0.07) | |
Diabetes mellitus | −0.13 (0.32) | −0.18 (0.22) | − 0.14 (0.44) | |
Vintage (months) | −0.11 (0.42) | −0.10 (0.50) | − 0.08 (0.62) | |
Betablockers | 0.14 (0.38) | 0.12 (0.46) | ||
ACEi/ARBs | −0.21 (0.19) | −0.21 (0.21) | ||
Statins | 0.18 (0.31) | 0.18 (0.31) | ||
PTH (ng/L) | −0.01 (0.93) | |||
Orosomucoid (g/L) | 0.14 (0.56) |